AMD is the leading cause of visual impairment and blindness in people over the age of 50 years. The number of people with this disease is estimated at 200 million worldwide and this number is expected to increase in 20 years by 50 %.. In 2010 there was a direct healthcare systems expenditure of $255 billion associated with AMD and this is expected to increase to $294 billion dollars by the year 2020 . Although it is such a common pathology there is no treatment available for dry AMD to improve vision or even stop the progression of the disease.
Ophthalmos publishes the results of using high doses of mainly EPA fatty acids on macular degenerations and dry eyes.
Click here for a published summary of results
